Waghralkar and Jhunjhunwala: Observational case studies of the effect of phage laden Ganga water on psoriasis


A number of dermatological disorders are caused by the microbiome.1 Scientists have suggested that the anti-microbial action of phages could help treat dermatological disorders.2 The exact method of action of the phages may often not be known.3 However, that does not prevent us from undertaking experimental treatment of dermatological disorders by phage therapy (PT). Providing relief to the patient is the primary objective of the medical profession.

PT has been used to treat a number of bacterial infections such as from Pseudomonas Aeruginosa,4, 5, 6, 7, 8 Staphylococcus Aureus,5, 6, 7 Acinetobacter, 6, 7 Enterobacteriaceae,6 Escherichia,8 Klebsiella, 7 and Streptococcus.8 Normally PT uses specific phages to treat specific bacterial infections. However, in the case of dermatological disorders, where possibly a number of bacterial infections are required to be simultaneously treated, a cocktail of phages could be more effective. The use of a cocktail of phages have been made to simultaneously target S. aureus, S. pyogenes, P. mirabilis, P. vulgaris, P. aeruginosa, and E. coli was used.8 The use of a cocktail is also preferred because the chances of emergence of phage resistance are reduced. 6

The established method of making a cocktail of phages is to first isolate a number of phages, multiply them, mix them and then administer them to the patient.9, 10 This process is expensive and faces the problem of maintaining stability of phages in the cocktail.8 We make a novel advance of administering the naturally available cocktail of phages in the Ganga river. The National Environment Engineering Research Institute, Nagpur has undertaken detailed survey of the presence of phages in the Ganga river. They have found that the water of the upper Ganga river contained more than 200 isolates of phages.11 More specifically, they have reported that phages having bactericidal activity against Mycobacterium, Streptococcus, Pseudomonas, Yersinia, Salmonella, Staphylococcus, Klebsiella, Vibrio, Shigella, Clostridium, Acinetobacter, Erwinia, Aeromonas, Escherichia, Cronobacter, Enterobacteria, and Campylobacter etc. are found in the Ganga waters. This unparalleled availability of large number of isolates gave us the reason to try treating chronic Psoriasis patients by cocktail phage therapy.

Psoriasis comes under papulosquamous disorder with a morphological feature of scaly papules and plaques. Psoriasis is an autoimmune disorder of the skin results in hyper proliferation of the skin. The itch scraping causes multiple bleeding points. Psoriatic lesions are distributed symmetrically on scalp, elbow, knees, lumbo-sacral area and in folds of body. Genetic factors play important role in its aetiology. There is a 7 percent chance that a person will contract psoriasis if one parent has psoriasis; and chances are 14 percent if both parents have psoriasis.

Type 1 psoriasis occurs at or before the age of 40 and seen in 75% of patients. Type II Psoriasis presents after the age of 40, with a peak at 55-60 years of age. The course of disease is chronic though periods of complete remission do occur. This is further divided to 3 subtypes. Acute form is characterized by small eruption and is accompanied by slight itching. This form is characteristic of psoriasis in childhood and young adults. Chronic plaque psoriasis with guttate exacerbation is seen in adults wide spread small plaque (< 3 cm) psoriasis. Nail psoriasis has been reported 40-50% of psoriatic patients.

Materials and Methods

The water of Ganga river upstream of Rudra Prayag, from where we have collected the same, has Dissolved Oxygen as 9.6 mg/liter and Biological Oxygen Demand at 1.2 mg/liter as per Government Reports. These levels meet the water quality standards for drinking water. The pH is reported to be between 6.5 to 8.5 which too meets the drinking water quality standards. However, the water had coliforms at 9300 per 100 ml against the requirement of less than 50 for drinking water.12 We tested the water after one month of storage and found that the phages adsorbed in the sediments had cleared the overlaying column of water of coliforms indicating that the water was fit for drinking.

We administered Ganga water orally to 38 patients having chronic psoriasis of two or more years. They were administered Ganga water in addition to the Ayurvedic prescription medicines which the patients had been taking since previously. All patients were not getting relief from the prescription medicines. The results seen in the present study can be attributed to Ganga water only because the prescription medicines had been continued and PT was added to the same. The patients were informed that they were being given Ganga water and their consent was taken.

Indeed, it cannot be totally precluded that the results reported here could be due to the prolonged use of the prescription medicines. However, that is not likely because they had been using the prescription medicines for more than two years without relief at the time that PT was added.

The protocol for intake was as follows:

  1. 10 ml Ganga water twice a day, half hour before meals

  2. Avoid taking any hot liquid (tea, coffee, etc.) immediately after consuming Ganga water.

The 1st phase of administration of Ganga water was 2 weeks followed by rest period of 2 weeks.

The 2nd phase of administration was 1 month followed by rest period of 1 month.

All patients having psoriasis were selected for the study.

The study size was determined by the number of psoriasis patients that came to the physician for treatment.

Inclusion criteria

Suffering from psoriasis, adult.

Exclusion criteria

Young below 18 years, pregnant, neurosis.

The result was scored on 1 to 10 Likert scale as assessed by the medical practitioner to assess the results, 13, 14 with “5” and less representing a “morbid” situation, and “10” representing best situation.

The results were recorded at 5 points of time:

Table 1

Results at four phases (All figures of “level” n Likert Scale of 1-10).

S. No


Prescribed Medicines

Phase I

Phase II Rest 2 weeks

Phase III Oral intake for 1 month

Phase IV Rest 1 month



Khadristria Syp 2-2 spoon, kheir 5 gm, sariwa 5 gm, Nagarmotha 5 gm, Bawachi 5 gm, Kamdudha 5 gm, Kanchnar guggulu 5 gm, 30 Pudies- 1-1 days

Patient showed improvement to level 1.5.

Morbidity relapsed to pre- treatment level with no improvement.

Improvement came back to level 1.5.

Patient remains at same level 1.5. No relapse.


54 yrs.

Raktashodka syp 2-2 spoon, Cap Atrisor 2-2/ 2 times, Bruhadaltaphal oil

Improvement of level 4-5.

Morbidity relapsed to pre-treatment level with no improvement.

Improved to level 5-6.

Improvement maintained at level 6. No relapse.


31 yrs.

Dermatone Syp, Cap. Finbid 1-1 /30, Cap Visora 2-2/60,

Improvement of level 4-5.

Morbidity relapsed to pre- treatment level with no improvement.

Improved to level 5.

Improvement maintained at level 5. No relapse.


71 yrs.

Raktashodka Syp 2-2, Tab Kanchnar guggul 2-2/tab 120, Bruhatdantfal oil, kheir 10 gm, sariwa 10 gm, Nagarmotna 10 gm, Bawachi 10 gm, Kamdudha 10 gm Kanchnar guggulu 5 gm Gulwelsatwl 10 gm, 60 Pudies- 1-1 days

Patient showed improvement to level 2.

Morbidity relapsed to pre- treatment level with no improvement.

Improvement increased to level 2.5.

Patient maintained at level 2.5.


40 yrs.

Tab Kanchnar guggul 2-2/tab 120, Bruhatdantfal oil, Atrisor oint Khadristria syp, kheir 10 gm, sariwa 10 gm, Nagarmotna 10 gm Bawachi 10 gm, Kamdudha 10 gm , Kanchnar guggul 10 gm, Gulwelsatwl 10 gm. 60 Pudies 1-1/days

Improvement at level 4.

Morbidity relapsed to pre- treatment level with no improvement.

Improved back to level 4 as at the end of Phase I.

No change. Improvement remains at level 4.


31 yrs.

Tab Kanchnar guggul 2-2/tab 120, 777 oil Psoralin oint, Dermation syp, kheir 10 gm, sariwa 10 gm, Nagarmotna 10 gm, Bawachi 10 gm, Kamdudha 10 gm, Kanchnar guggul 10 gm, Gulwelsatwl 10 gm, 60 Pudies 1-1/days

Patient showed improvement at level 3.

Morbidity did not relapse.

Improvement remained at level 3.

Patient remains at same level 3 of improvement.


78 Yrs.

Tab Kanchnar guggul 2-2/tab 120, Psora oil , Trichoden oint, Bactimo syp, kheir 10 gm, sariwa 10 gm, Nagarmotna 10 gm, Bawachi 10 gm, Kamdudha 10 gm, Kanchnar gu 10 gm ,Gulwelsatwl 10 gm, 60 Pudies 1-1/days

Patient showed improvement at level 2.

Morbidity relapsed to pre-treatment level.

Improvement is same at level 2.

Improvement remains same at level 2 with no relapse.


22 Yrs.

Tab Kanchnar guggul 2-2/tab 120, Raktufi syp, Bruhatdantfal oil, Atrosor oil, kheir 10 gm, sariwa 10 gm, Nagarmotna 10 gm, Bawachi 10 gm , Kamdudha 10 gm , Kanchnar guggul 10 gm , Gulwelsatwl 10 gm, 60 Pudies 1-1/days

Improvement at level 5.

Morbidity relapsed to pre-treatment level.

Improvement is same at level 5.

Improvement remains at same level 5 with no relapse.











Figure 1
Figure 2

Beginning of treatment

Phase I, Administered: Ganga water was administered. Change before and after administration was recorded.

Phase II, Rest: Ganga water was stopped and change at the end of the rest was recorded.

Phase III, Administered: Ganga water was administered. Change at the end of administration was recorded.

Phase IV, Rest: Status was recorded 4 weeks after stoppage of treatment.

Thirty eight patients were included in the study initially. 18 patients did not take interest in the treatment during Phase I itself leaving 20 patients who completed the treatment in Phase I. Of these, 3 did not continue in phase III because they did not find benefit in Phase I while 5 did not continue in phase III even though they got some benefit in Phase I. This left 12 patients who took Treatment in Phase III. Of these 12 patients, 4 did not cooperate in providing report of the final result after Phase IV. Hence, we report the results of the 8 patients who took treatment in Phase I and III and cooperated in providing the results.

Results & Discussion

We present the results both in average and median. Average is calculated by summing the values and dividing by the numbers of observations. This is sensitive to one or few observations showing high numbers. Thus, median is considered to be more robust.15

The 8 patients showed a median improvement of 2.5 (range from 1 to 3.5) in Phase I of 15 days of administration. The improvement relapsed to original level showing no improvement (from 3.5 to 1) although one patient (Number 6) reported no relapse. A median improvement of 2.5 (from 1 to 3.5) was again recorded in Phase III of 30 days of administration. This improvement held at level 3.5 and did not relapse at the end of Phase IV of Rest.

Limitations of the study are as follows. One, the confounding effect of normal prescription medicines cannot be precluded though it is not likely because the patients had been suffering from psoriasis for 2 years or more and had been taking the prescription medicines. Two, the sample size was small. However, oftentimes an experimental treatment can open up new vistas.16 Three, only one protocol was adopted. It is necessary to try different protocols and arrive at the most robust protocol. Four, at the end of Phase IV, four patients reported improvement to level 4-6 while four reported improvement to level 1-3. A longer treatment period needs to be tried to ascertain if greater improvement is obtained.

A limitation of the study is that the exact numbers and species of phages are not identified. Therefore, it is possible that water taken from the Ganga river at another place and time may have a different combination of phages that may or may not be effective for treatment.


Conclusion is that Ganga water therapy holds much potential for the treatment of psoriasis if the treatment is made for minimum four weeks.


Drs. Narendra Nath Mehrotra, Amitabh Satsangi, Anil Gourishetty, Arvind Pandey, Sukhdev Singh and Surabhi Puri have provided extremely valuable help in conceiving and planning the study.



DP Britta G Lynda D Melanie M Aglaya P Bernhard C Chris Gut–Skin Axis: Current Knowledge of the Interrelationship between Microbial Dysbiosis and Skin ConditionsMicroorganisms202192353


G Andrej BL Paul P Maciej B Jan M Ryszard JM Ewa Perspectives of Phage Therapy in Non-bacterial InfectionsFront Microbiol20189330610.3389/fmicb.2018.03306


M Prasanth AJ Tamhankar L Sebastian R Nachimuthu Ramesh Nachimuthu Pharmacological and Immunological Aspects of Phage TherapyInfect Microbes Dis2019123442


DP Pires DV Boas S Sillankorva J Azeredo Phage Therapy: a Step Forward in the Treatment of Pseudomonas aeruginosa InfectionsJ Virology2015891574495610.1128/JVI.00385-15


M Merabishvili J-P Pirnay G Verbeken N Chanishvili M Tediashvili Quality-Controlled Small-Scale Production of a Well-Defined Bacteriophage Cocktail for Use in Human Clinical TrialsPLoS ONE2009434944


RG Wunderink Turning the Phage on Treatment of Antimicrobial-Resistant PneumoniaAm J Respir Crit Care Med2019200910.1164/rccm.201908-1561ED


MS Rezai G Rahimzadeh Phage Therapy to Prevent Nosocomial Bacterial Pneumonia in Patients with Severe COVID-19 in 2020Am J Biomed Sci Res202010510.34297/AJBSR.2020.10.001563 Abstract


R Yoon K Chang M Wallin Y Lin SSY Leung H Wang Phage Therapy for Respiratory InfectionsAdv Drug Deliv Rev2018133768610.1016/j.addr.2018.08.001


W Marcin Wojewodzic Bacteriophages Could Be a Potential Game Changer in the Trajectory of Coronavirus Disease (COVID-19)Ther Appl Res20201260510.1089/phage.2020.0014


A Martinecza MW Wojewodzic Could bacteriophages be the answer to the COVID-19 crisis? Expert Rev Anti-infective Ther2020195557810.1080/14787210.2021.1836960


National Environment Research Institute, Ganga Study2018544https://nmcg.nic.in/writereaddata/fileupload/NMCGNEERI%20Ganga%20Report.pdf


12.Central Pollution Control Board, Pollution Assessment: River Ganga2103https://cpcb.nic.in/wqm/pollution-assessment-ganga-2013.pdf


Versta Research, How to Label Your 10-Point Scalehttps://verstaresearch.com/blog/how-to-label-your-10-point-scale/


F Decker How to Interpret Likert Surveys, Sciencing, March 2018http://sciencing.com/interpret-likert-surveys-8573143.html


JD Cook Example of efficiency for mean vs. median2009http://www.johndcook.com/blog/2009/03/06/student-t-distribution-mean-median/


R D Truog The UK sets limits on experimental treatmentsJAMA2017318111001210.1001/jama.2017.10410


© This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

  • Article highlights
  • Article tables
  • Article images

Article History

Received : 22-06-2021

Accepted : 03-08-2021

Available online : 04-09-2021

View Article

PDF File   Full Text Article


PDF File   XML File   ePub File

Digital Object Identifier (DOI)

Article DOI


Article Metrics

Article Access statistics

Viewed: 90

PDF Downloaded: 26

Wiki in hindi